OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...

Urcosimod has received FDA fast track designation for neuropathic corneal pain, enabling expedited regulatory processes and ...

The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

US FDA grants fast track designation to OKYO Pharma’s urcosimod to treat neuropathic corneal pain: London Saturday, May 3, 2025, 17:00 Hrs [IST] OKYO Pharma Limited, an ophthalm ...

NCP is a debilitating condition characterized by severe pain and sensitivity of the eyes, face, or head, often due to nerve damage and inflammation of the cornea. Currently, there is no FDA ...

OKYO Pharma remains dedicated to advancing urcosimod through clinical development and regulatory review, with a focus on addressing the significant unmet medical need in neuropathic corneal pain ...

Post-intensive care syndrome (PICS) is highly prevalent in ICU patients. This article explains key signs and symptoms.

NCP is a debilitating condition characterized by severe pain and sensitivity of the eyes, face, or head, often due to nerve damage and inflammation of the cornea. Currently, there is no FDA-approved ...